Renata Cristina Rezende Macedo do Nas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1319915/publications.pdf

Version: 2024-02-01

840776 752698 23 434 11 20 citations h-index g-index papers 25 25 25 689 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Key characteristics including sex, sexual orientation and internet use associated with worse mental health among university students in Brazil and implications. Journal of Public Health, 2022, 44, e487-e498.	1.8	2
2	Effects and implications of the COVID-19 pandemic on medicine use by employees of a Brazilian public university: a cross-sectional study. Sao Paulo Medical Journal, 2022, , .	0.9	0
3	Public Programs for Essential Medicine Access in a Small Municipality: A Cross-Sectional Analysis. International Journal of Cardiovascular Sciences, 2022, , .	0.1	O
4	Regulatory intelligence of health technologies in Greece. Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde, 2022, 13, 789.	0.1	0
5	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2021, 10, 243-253.	1.4	4
6	Prevalence and factors associated with anxiety among university students of health sciences in Brazil: findings and implications. Jornal Brasileiro De Psiquiatria, 2021, 70, 99-107.	0.7	7
7	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021, 10, 519-532.	1.4	4
8	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life, 2021, 11, 528.	2.4	95
9	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. Frontiers in Public Health, 2021, 9, 671961.	2.7	22
10	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. Journal of Comparative Effectiveness Research, 2021, 10, 869-879.	1.4	3
11	A new Brazilian regional scenario of Type 2 diabetes risk in the next ten years. Primary Care Diabetes, 2021, 15, 1019-1025.	1.8	1
12	COVID-19 in medium-sized municipalities in the 14 health macro-regions of Minas Gerais, Brazil. Brazilian Journal of Medical and Biological Research, 2021, 54, e11191.	1.5	O
13	Realâ€world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish populationâ€based study. British Journal of Clinical Pharmacology, 2020, 86, 2349-2361.	2.4	16
14	Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 1-26.	1.4	47
15	Statin use in Brazil: findings and implications. Current Medical Research and Opinion, 2018, 34, 1809-1817.	1.9	21
16	Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 655-666.	1.4	32
17	Use of medicines by patients of the primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 18s.	1.7	18
18	Financing of Pharmaceutical Services in the municipal management of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 14s.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Polypharmacy:. Revista De Saude Publica, 2017, 51, 19s.	1.7	43
20	Availability of essential medicines in primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 10s.	1.7	44
21	Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health System (Sus) – Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide – In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. Value in Health, 2015, 18, A862.	0.3	1
22	Authors' Reply to Dr. Malerbi: "Insulin Glargine in a Brazilian State: Should the Government Disinvest?― Applied Health Economics and Health Policy, 2014, 12, 561-563.	2.1	2
23	Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review. Applied Health Economics and Health Policy, 2014, 12, 19-32.	2.1	46